180 related articles for article (PubMed ID: 26476745)
21. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
22. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Yamazaki H; Shirakawa K; Matsumoto T; Kazuma Y; Matsui H; Horisawa Y; Stanford E; Sarca AD; Shirakawa R; Shindo K; Takaori-Kondo A
PLoS One; 2020; 15(1):e0223463. PubMed ID: 31914134
[TBL] [Abstract][Full Text] [Related]
23. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
Wang D; Li X; Li J; Lu Y; Zhao S; Tang X; Chen X; Li J; Zheng Y; Li S; Sun R; Yan M; Yu D; Cao G; Yang Y
Gut; 2019 Oct; 68(10):1846-1857. PubMed ID: 31154396
[TBL] [Abstract][Full Text] [Related]
24. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
25. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
[TBL] [Abstract][Full Text] [Related]
26. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
[TBL] [Abstract][Full Text] [Related]
28. ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells.
Kazuma Y; Shirakawa K; Tashiro Y; Yamazaki H; Nomura R; Horisawa Y; Takeuchi S; Stanford E; Konishi Y; Matsui H; Matsumoto T; Tanabe F; Morishita R; Ito S; Takaori-Kondo A
Sci Rep; 2022 Feb; 12(1):2278. PubMed ID: 35145187
[TBL] [Abstract][Full Text] [Related]
29. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
[TBL] [Abstract][Full Text] [Related]
30. Human APOBEC3B interacts with the heterogenous nuclear ribonucleoprotein A3 in cancer cells.
Mishra N; Reddy KS; Timilsina U; Gaur D; Gaur R
J Cell Biochem; 2018 Aug; 119(8):6695-6703. PubMed ID: 29693745
[TBL] [Abstract][Full Text] [Related]
31. In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.
Ohba K; Ichiyama K; Yajima M; Gemma N; Nikaido M; Wu Q; Chong P; Mori S; Yamamoto R; Wong JE; Yamamoto N
PLoS One; 2014; 9(5):e97787. PubMed ID: 24858917
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3B is preferentially expressed at the G2/M phase of cell cycle.
Hirabayashi S; Shirakawa K; Horisawa Y; Matsumoto T; Matsui H; Yamazaki H; Sarca AD; Kazuma Y; Nomura R; Konishi Y; Takeuchi S; Stanford E; Kawaji H; Murakawa Y; Takaori-Kondo A
Biochem Biophys Res Commun; 2021 Mar; 546():178-184. PubMed ID: 33592502
[TBL] [Abstract][Full Text] [Related]
33. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR; Gui P; Mayekar MK; Law EK; Pich O; Bailey C; Boumelha J; Kerr DL; Blakely CM; Manabe T; Martinez-Ruiz C; Bakker B; De Dios Palomino Villcas J; I Vokes N; Dietzen M; Angelova M; Gini B; Tamaki W; Allegakoen P; Wu W; Humpton TJ; Hill W; Tomaschko M; Lu WT; Haderk F; Al Bakir M; Nagano A; Gimeno-Valiente F; de Carné Trécesson S; Vendramin R; Barbè V; Mugabo M; Weeden CE; Rowan A; McCoach CE; Almeida B; Green M; Gomez C; Nanjo S; Barbosa D; Moore C; Przewrocka J; Black JRM; Grönroos E; Suarez-Bonnet A; Priestnall SL; Zverev C; Lighterness S; Cormack J; Olivas V; Cech L; Andrews T; Rule B; Jiao Y; Zhang X; Ashford P; Durfee C; Venkatesan S; Temiz NA; Tan L; Larson LK; Argyris PP; Brown WL; Yu EA; Rotow JK; Guha U; Roper N; Yu J; Vogel RI; Thomas NJ; Marra A; Selenica P; Yu H; Bakhoum SF; Chew SK; Reis-Filho JS; Jamal-Hanjani M; Vousden KH; McGranahan N; Van Allen EM; Kanu N; Harris RS; Downward J; Bivona TG; Swanton C
Nat Genet; 2024 Jan; 56(1):60-73. PubMed ID: 38049664
[TBL] [Abstract][Full Text] [Related]
34. APOBEC3B is an enzymatic source of mutation in breast cancer.
Burns MB; Lackey L; Carpenter MA; Rathore A; Land AM; Leonard B; Refsland EW; Kotandeniya D; Tretyakova N; Nikas JB; Yee D; Temiz NA; Donohue DE; McDougle RM; Brown WL; Law EK; Harris RS
Nature; 2013 Feb; 494(7437):366-70. PubMed ID: 23389445
[TBL] [Abstract][Full Text] [Related]
35. B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers.
Chou WC; Chen WT; Hsiung CN; Hu LY; Yu JC; Hsu HM; Shen CY
Sci Rep; 2017 Mar; 7():44089. PubMed ID: 28276478
[TBL] [Abstract][Full Text] [Related]
36. Unfavorable prognosis and clinical consequences of APOBEC3B expression in breast and other cancers: A systematic review and meta-analysis.
Jafarpour S; Yazdi M; Nedaeinia R; Ghobakhloo S; Salehi R
Tumour Biol; 2022; 44(1):153-169. PubMed ID: 36093650
[TBL] [Abstract][Full Text] [Related]
37. The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.
McCann JL; Klein MM; Leland EM; Law EK; Brown WL; Salamango DJ; Harris RS
J Biol Chem; 2019 Aug; 294(32):12099-12111. PubMed ID: 31217276
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Shigaki H; Kurashige J; Hiyoshi Y; Iwatsuki M; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Oki E; Watanabe M; Baba H
Med Oncol; 2016 Mar; 33(3):26. PubMed ID: 26880326
[TBL] [Abstract][Full Text] [Related]
39. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
[TBL] [Abstract][Full Text] [Related]
40. APOBEC3B Nuclear Localization Requires Two Distinct N-Terminal Domain Surfaces.
Salamango DJ; McCann JL; Demir Ö; Brown WL; Amaro RE; Harris RS
J Mol Biol; 2018 Aug; 430(17):2695-2708. PubMed ID: 29787764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
